| Autor: |
SYED, G. M. SHAH, MAKEN, R. N., MUZZAFFAR, N., SHAH, M. A., RANA, F. |
| Zdroj: |
Nuclear Medicine Communications; August 1999, Vol. 20 Issue: 8 p697-702, 6p |
| Abstrakt: |
The role of phosphorus-32 (32P) was evaluated in patients experiencing pain due to skeletal metastases from prostate cancer and refractory to other modes of treatment. Twenty patients received 185 MBq (5 mCi) 32P intravenously; 12 patients received a single dose each, five patients were injected twice and three patients three times at 3-month intervals. A blood count and clinical assessment for bone pain, tender sites, mobility and analgesic intake were performed before and 4, 8 and 12 weeks after the administration of 32P. A bone scan was performed before and 12 weeks after therapy. The results showed a significant decrease in pain at 4 weeks and a palliative response persisted for up to 12 weeks. Analgesic medication intake decreased significantly (F= 13.2213, P< 0.0001) and mobility improved after therapy. Quantitative analysis of the bone scans showed a statistically significant reduction in osteoblastic activity in metastatic lesions after therapy (t= −3.80, P< 0.001). Transient myelosuppression after 4 weeks, which was statistically significant for WBC and platelet counts only (F= 3.0226, P= 0.0358; F= 6.2514, P= 0.0009 respectively), returned within normal limits by 8 weeks. We conclude that 32P is an effective and safe therapy for pain palliation. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
